Analysis of public databases validated the elevated PAFAH1B3 expression in lung adenocarcinoma and positioned PAFAH1B3 as a promising candidate for prognostic marker and potential therapeutic target in lung cancer treatment [38]. This evidence concerns the gene PAFAH1B3 and lung adenocarcinoma.